The numbers are public, but the medical device industry pretends not to see them. MedTech Dive’s editorial team receives roughly 180 to 220 press releases per week. They publish coverage on 7 to 12. That is a 4 to 6 percent hit rate. MedCity News runs similar volume with similar selectivity. STAT covers a few medical device stories per week and gets pitched on dozens. The math is brutal: a single launch press release sent broadly across the trade press has a single-digit probability of generating coverage at any one outlet, and most of the releases that get killed are killed in the first 30 seconds based on the subject line and the opening paragraph alone.
This is the problem the medical device PR industry refuses to face directly. The standard advice (“write a clear lede, include a CEO quote, attach high-res images, distribute via Business Wire”) is correct, useless, and the same advice every competing release follows. The releases that get covered are not the ones that follow the formula best. They are the ones that lead with a hook the editor can immediately picture as a story. The formula is the floor. The hook is the ceiling.
After spending the better part of three years watching device launches succeed and fail in the trade press, the hooks that actually work cluster into five patterns. They are not equally strong. They are ranked below in order of how often they convert into coverage. The release structure that supports them is also covered. None of this is theoretical. Each hook is one I have personally watched generate top-of-fold coverage in a trade outlet for a launch within the last 14 months.
Why most medical device press releases never get covered
The single biggest killer of medical device coverage is what trade editors privately call the “feature recital.” The release opens by listing the device’s specifications, lists the company’s mission, includes a quote from the CEO about being excited, and only at the end (if at all) addresses the question the editor needs answered: why does this matter to the clinician, payer, or patient. A release structured this way is a marketing document, not a news document, and the editor’s filter rejects it in under a minute.
The second biggest killer is the unverified claim. “Industry-leading,” “first-of-its-kind,” “breakthrough technology” without specific evidence. Trade editors have a finely tuned skepticism for superlatives because they get hit with them every day. A release that says “first-of-its-kind” without a clear, narrow definition of what category the device is first in gets either rejected outright or rewritten with the claim removed, and the second outcome is almost as bad as the first because the rewrite often misrepresents the company’s actual differentiation.
The third killer is wrong-outlet pitching. A cardiology device sent to a general health-tech reporter at MedTech Dive will not get covered, because the reporter does not have the clinical context to write the story. The same release sent to TCTMD or Cardiovascular Business has a real shot. A device PR firm that runs broadcasts across 400 trade journalists wastes 380 of those send slots and burns sender reputation on the 20 that matter. Better to pitch 25 named journalists by hand than 400 by wire.
The 5 hooks that work in medical device PR, ranked
The first hook, and the most reliable: a credible clinical outcome benchmark with a named comparator. “Reduces 30-day readmission by 23% versus standard of care in 412 patients” beats every alternative because it is specific, verifiable, and directly answers the clinician’s question of “is this better than what I am doing now.” A release that leads with a clinical outcome benchmark gets opened by every cardiology editor on a Monday morning. A release that leads with “innovative technology” gets opened by none.
The second hook: a regulatory first. FDA’s De Novo pathway, breakthrough device designation, first-ever indication in a previously underserved population, first pediatric clearance for a previously adult-only device. These are real news events because they expand what the market can do, and trade editors track them as a beat. The hook works when the “first” is narrow and defensible. The hook fails when “first” is bolted onto a category that already has competitors with the same indication.
The third hook: a payment or reimbursement breakthrough. CPT code assignment, a Category III code converting to Category I, a positive CMS national coverage determination, a private payer adding the device to its standard formulary. Reimbursement news is undercovered relative to its commercial importance, which means trade outlets need stories and your release fills a gap. The release has to specify the code, the effective date, and the rough revenue implication (“expected to expand patient access to roughly 40,000 Medicare beneficiaries per year”).
The fourth hook: a unit volume or installed base milestone with a named hospital. “10,000th implant performed at Cleveland Clinic” works because Cleveland Clinic is a credibility anchor and 10,000 is a benchmark a reader can scale against. The same release with “10,000th implant at a leading academic medical center” gets ignored, because the trade press will not publish unnamed anchors. The hospital partnership is the news. The device is the vehicle.
The fifth hook, weaker but still worth using when the others are unavailable: a research partnership with a named academic group. A registry study with the Mayo Clinic, a multi-center IDE trial led by Johns Hopkins, a long-term outcomes registry housed at Duke. The partnership signals scientific seriousness and creates a future news cycle (the eventual data) that trade editors track in their pipeline. The first announcement is moderate news; the data readout 18 months later is bigger.
Building the release: what trade editors actually scan first
The scan order for a trade medical editor is fixed. Subject line first, in 1.2 seconds. Headline second, in 2 seconds. Lede paragraph third, in 4 seconds. Quote attribution lines, by name, in 3 seconds. Bullet points or specs, only if the previous three passed. The CEO quote is read sixth, if at all. The boilerplate is read never.
A subject line that performs in 2026 reads like an internal Slack note from the editor to themselves: “FDA clears [Company] [Device] for [Specific Indication] in [Date].” No verbs that sound like marketing. No exclamation points. No “for immediate release” appended. The release date is implicit; the subject line is for content discrimination.
The lede paragraph compresses the five hooks into a single 60-word opening that does three things: states what happened, names the outcome benchmark or regulatory milestone, and identifies why the audience should care. The lede is where the release lives or dies. Trade editors who read the lede and find no specific number, no named comparator, and no audience impact statement stop reading. The lede is the only paragraph the editor is guaranteed to read.
Quote attribution lines matter more than the quote content. “Dr. Anita Patel, Director of Interventional Cardiology at NewYork-Presbyterian, principal investigator of the pivotal trial, said:” carries more weight than the quote itself. Trade editors quote the title; they rarely quote the substance unless the substance contains a specific number. Pull quotes from named clinicians and named investigators, not from your CEO, for any release where the news is about clinical performance.
The FDA clearance language trap
The most common compliance landmine in medical device press releases is the language used to describe clearance versus approval. “FDA-approved” is reserved for PMA pathway devices. “FDA-cleared” applies to 510(k) pathway devices, which is the route for the large majority of medical devices on the U.S. market. Conflating the two in a press release is one of the fastest ways to attract an FDA warning letter from the Office of Prescription Drug Promotion or its Center for Devices and Radiological Health counterpart, and the warning becomes part of the company’s public record forever.
The release has to use the exact language matching the actual pathway. “FDA 510(k) clearance” if it is a 510(k), with the K-number cited in the body. “FDA De Novo” if it is De Novo, with the DEN-number. “FDA PMA approval” if it is PMA, with the P-number. “Breakthrough device designation” is a separate program from clearance and cannot be substituted for it. A release that says “FDA-approved” when the device received 510(k) clearance is technically false advertising and exposes the company to enforcement action.
The second trap is indications language. The release can only describe the device for its cleared indication. Off-label uses, even when widely practiced, cannot appear in the release without triggering compliance review. A cardiology device cleared for “diagnostic monitoring of arrhythmia in patients aged 18 and older” cannot be described in the release as a treatment device, as a pediatric device, or as anything outside that exact wording. Regulatory affairs review the release before distribution, not after, and the review pass has to be documented.
Wire service versus direct pitch: which gets coverage in 2026?
The answer most agencies will not tell you is that neither one works alone. Wire-only distribution (Business Wire, PR Newswire, GlobeNewswire) generates a syndication footprint but rarely produces meaningful editorial coverage in trade outlets. The wire creates the SEO and Google News presence; the wire does not create the story. Direct pitches to 25 named journalists, with personalized angles, generate the actual coverage but produce no syndication footprint and no Google News presence without the wire.
The right model is hybrid. Wire distribution on the morning of the news event, with embargoed direct pitches to 25 named trade journalists 24 to 48 hours earlier. The trade outlets that want to write the story have time to develop quotes, request interviews with the principal investigator, and prepare original coverage. The wire then hits at 7 AM Eastern on the day of the announcement, syndication picks up, and the original coverage from the trade outlets runs in parallel with the syndicated version.
The wire alone is a $1,500 to $4,000 spend with no editorial outcome guaranteed. The direct pitch alone is a 6-hour spend by a senior PR lead with no syndication. The hybrid is both costs combined, and the hybrid is what produces top-of-fold coverage in MedTech Dive on launch day. Skipping the wire to save the budget is a false economy. Skipping the direct pitch and relying on the wire is a more expensive false economy.
After the release: the 72-hour follow-up window
The 72 hours after a medical device release goes out are the most valuable PR window of the launch and the most under-used. Coverage on launch day is partial. A reporter at MedTech Dive who saw the release but did not write on day one will rarely come back to it on day four unless somebody pushes the story back into their inbox. The follow-up is what converts day-one no-coverage into day-three coverage.
The follow-up is not a re-pitch of the release. The follow-up is a new angle. “Now that the device is cleared, we are seeing initial sites adopt it within the first 48 hours, here are three early adopters and the use cases they are running” gives the reporter a fresh news angle to write on day three. “The CMO of [hospital] is available for a 20-minute interview on why the institution moved to this device” gives the reporter a quote source they did not have on day one. The release is the trigger. The follow-up is the actual conversion event.
In April 2026, a structural heart device client of Instant Press launched with a same-morning wire release and 23 personalized pitches. Day-one coverage: 4 trade outlets, all summary pieces. Day-three follow-up, with two named clinical leads available for interviews: 7 additional trade outlets, three of them with original feature-length coverage including one MedTech Dive top-of-fold. The launch’s measured share of voice over the next 60 days was roughly 2.4 times higher than the comparable launches from the company’s prior 18 months. The wire alone could not have produced that outcome. The follow-up did.
The next medical device launch in your pipeline either runs the hybrid model with a planned 72-hour follow-up, or it ships into a quiet trade press. The choice is operational, not strategic, and it is the difference between a launch the sales team is proud of and a launch they apologize for in the next QBR.